Literature DB >> 21731057

Initial interrogation, confirmation and fine mapping of modifying genes: STAT3, IL1B and IFNGR1 determine cystic fibrosis disease manifestation.

Heike Labenski1, Silke Hedtfeld, Tim Becker, Burkhard Tümmler, Frauke Stanke.   

Abstract

We have used a stepwise approach consisting of initial interrogation, confirmation and fine mapping to analyze STAT3, IL1B and IFNGR1 as modifiers of cystic fibrosis disease building upon the data and sample collection of the European Cystic Fibrosis Twin and Sibling Study. We have observed direct correlation between the length of the intronic microsatellite STAT3Sat to STAT3 expression levels among F508del-CFTR homozygous patients (P=0.0075), and an association of longer STAT3Sat-alleles with the presence of CFTR-mediated residual chloride secretion (P=0.0031), measured as the manifestation of the CF basic defect in intestinal tissue. Both, family-based analysis by TDT and case-reference comparison identified consistently the same intragenic IL1B haplotype as a risk variant (P(raw)=0.055 for TDT, P(raw)<0.3 for case-reference comparison). Using haplotype-guided hierarchical fine mapping, we have identified two single nucleotide exchanges for which concordant and discordant sibling pairs differ at a 7 kb-spanning core haplotype in IFNGR1 (P(raw)=0.0113). Taken together, our findings imply that immunorelevant pathways and ion secretion, dominated by CFTR in intestinal and respiratory epithelium, merge at the level of the epithelial cell to integrate the signaling of cytokines due to innate and acquired immune defense.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21731057      PMCID: PMC3230365          DOI: 10.1038/ejhg.2011.129

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  54 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

2.  Reduction of alveolar epithelial ion and fluid transport by inflammatory mediators.

Authors:  Michael Eisenhut
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03       Impact factor: 6.914

3.  Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.

Authors:  David S Armstrong; Sarah M Hook; Kris M Jamsen; Gillian M Nixon; Rosemary Carzino; John B Carlin; Colin F Robertson; Keith Grimwood
Journal:  Pediatr Pulmonol       Date:  2005-12

4.  Genetic modifiers of lung disease in cystic fibrosis.

Authors:  Mitchell L Drumm; Michael W Konstan; Mark D Schluchter; Allison Handler; Rhonda Pace; Fei Zou; Maimoona Zariwala; David Fargo; Airong Xu; John M Dunn; Rebecca J Darrah; Ruslan Dorfman; Andrew J Sandford; Mary Corey; Julian Zielenski; Peter Durie; Katrina Goddard; James R Yankaskas; Fred A Wright; Michael R Knowles
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

5.  Transmission ratio distortion and maternal effects confound the analysis of modulators of cystic fibrosis disease severity on 19q13.

Authors:  Tim Becker; Silke Jansen; Stephanie Tamm; Thomas F Wienker; Burkhard Tümmler; Frauke Stanke
Journal:  Eur J Hum Genet       Date:  2007-04-04       Impact factor: 4.246

6.  Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis.

Authors:  Scott M Blackman; Rebecca Deering-Brose; Rita McWilliams; Kathleen Naughton; Barbara Coleman; Teresa Lai; Marilyn Algire; Suzanne Beck; Julie Hoover-Fong; Ada Hamosh; M Daniele Fallin; Kristen West; Dan E Arking; Aravinda Chakravarti; David J Cutler; Garry R Cutting
Journal:  Gastroenterology       Date:  2006-07-24       Impact factor: 22.682

Review 7.  Modifier genetics: cystic fibrosis.

Authors:  Garry R Cutting
Journal:  Annu Rev Genomics Hum Genet       Date:  2005       Impact factor: 8.929

8.  Interleukin-1beta decreases expression of the epithelial sodium channel alpha-subunit in alveolar epithelial cells via a p38 MAPK-dependent signaling pathway.

Authors:  Jérémie Roux; Hisaaki Kawakatsu; Brandi Gartland; Melissa Pespeni; Dean Sheppard; Michael A Matthay; Cecilia M Canessa; Jean-François Pittet
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

Review 9.  Cystic fibrosis: a review of epidemiology and pathobiology.

Authors:  Steven D Strausbaugh; Pamela B Davis
Journal:  Clin Chest Med       Date:  2007-06       Impact factor: 2.878

10.  The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis.

Authors:  Frauke Stanke; Tim Becker; Harry Cuppens; Vinod Kumar; Jean-Jacques Cassiman; Silke Jansen; Dragica Radojkovic; Benny Siebert; Jennifer Yarden; David W Ussery; Thomas F Wienker; Burkhard Tümmler
Journal:  Hum Genet       Date:  2006-02-04       Impact factor: 4.132

View more
  8 in total

1.  Effect of Alpha-1 Antitrypsin on CFTR Levels in Primary Human Airway Epithelial Cells Grown at the Air-Liquid-Interface.

Authors:  Frauke Stanke; Sabina Janciauskiene; Stephanie Tamm; Sabine Wrenger; Ellen Luise Raddatz; Danny Jonigk; Peter Braubach
Journal:  Molecules       Date:  2021-04-30       Impact factor: 4.411

Review 2.  The Contribution of the Airway Epithelial Cell to Host Defense.

Authors:  Frauke Stanke
Journal:  Mediators Inflamm       Date:  2015-06-21       Impact factor: 4.711

3.  β-Cryptoxanthin alleviates diet-induced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in mice.

Authors:  Masuko Kobori; Yinhua Ni; Yumiko Takahashi; Natsumi Watanabe; Minoru Sugiura; Kazunori Ogawa; Mayumi Nagashimada; Shuichi Kaneko; Shigehiro Naito; Tsuguhito Ota
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

4.  Changes in transcriptome of native nasal epithelium expressing F508del-CFTR and intersecting data from comparable studies.

Authors:  Luka A Clarke; Lisete Sousa; Celeste Barreto; Margarida D Amaral
Journal:  Respir Res       Date:  2013-03-28

5.  The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells.

Authors:  Frauke Stanke; Andrea van Barneveld; Silke Hedtfeld; Stefan Wölfl; Tim Becker; Burkhard Tümmler
Journal:  Eur J Hum Genet       Date:  2013-10-09       Impact factor: 4.246

Review 6.  Disease-modifying genes and monogenic disorders: experience in cystic fibrosis.

Authors:  Sabina Gallati
Journal:  Appl Clin Genet       Date:  2014-07-10

Review 7.  The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology.

Authors:  Marta Stolarczyk; Bob J Scholte
Journal:  Mediators Inflamm       Date:  2018-01-09       Impact factor: 4.711

Review 8.  Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine.

Authors:  Lăcrămioara Ionela Butnariu; Elena Țarcă; Elena Cojocaru; Cristina Rusu; Ștefana Maria Moisă; Maria-Magdalena Leon Constantin; Eusebiu Vlad Gorduza; Laura Mihaela Trandafir
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.